Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Retatrutide in Obese Participants
NCT05445232Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2022
- Primary completion
- Feb 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of retatrutide in obesity, sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam at 24 hours, Maximum Observed Concentration (Cmax) of Midazolam at 24 hours and 4 more. Started Jul 2022; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05445232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445232.